Cognition Therapeutics Inc (NASDAQ: CGTX) kicked off on Friday, up 41.21% from the previous trading day, before settling in for the closing price of $1.99. Over the past 52 weeks, CGTX has traded in a range of $0.22-$2.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -16.44%. While this was happening, its average annual earnings per share was recorded 51.45%. With a float of $59.05 million, this company’s outstanding shares have now reached $64.96 million.
Cognition Therapeutics Inc (CGTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cognition Therapeutics Inc is 19.63%, while institutional ownership is 7.17%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.25 earnings per share (EPS), lower than consensus estimate (set at -0.21) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 51.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.88% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Take a look at Cognition Therapeutics Inc’s (CGTX) current performance indicators. Last quarter, stock had a quick ratio of 1.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Looking closely at Cognition Therapeutics Inc (NASDAQ: CGTX), its last 5-days average volume was 10.35 million, which is a jump from its year-to-date volume of 4.73 million. As of the previous 9 days, the stock’s Stochastic %D was 89.50%.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 97.73%, which indicates a significant increase from 97.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.76, while its 200-day Moving Average is $0.55. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $3.12. Second resistance stands at $3.42. The third major resistance level sits at $3.98. If the price goes on to break the first support level at $2.26, it is likely to go to the next support level at $1.70. Now, if the price goes above the second support level, the third support stands at $1.40.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
The company with the Market Capitalisation of 206.45 million has total of 73,472K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -33,970 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,730 K.
